Oligodendrocyte
CNS myelin-forming glia; one mature oligodendrocyte myelinates 15–40 axon segments at conduction velocities ≥70 m/s via saltatory conduction. OPCs (NG2⁺/PDGFRα⁺) persist as adult progenitors. MCT1-derived lactate provides metabolic support to axons independent of insulation. Remyelination by OPCs fails in chronic MS lesions due to inhibitory microenvironment (LINGO-1, CSPG, Sema3A) and OPC senescence.
Overview
Oligodendrocytes are the myelin-forming glial cells of the central nervous system. Unlike Schwann cells (PNS — one cell per one axon segment), a single oligodendrocyte extends processes to myelinate 15–40 distinct axon internodal segments, each spanning 100–1500 µm in length and wrapped by approximately 150 compacted membrane layers. This architecture is highly efficient — a single oligodendrocyte can insulate hundreds of metres of axonal surface area in total.
The functional consequence of myelin is profound. Unmyelinated axons conduct at ~0.5–2 m/s via continuous propagation; myelinated axons conduct via saltatory conduction (action potentials jump between nodes of Ranvier where Nav channels cluster) at speeds of ≥70 m/s for large-diameter fibres. Myelination is therefore not merely insulation — it is a conduction velocity amplifier that makes the rapid sensorimotor integration, language, and cognitive functions of the large mammalian brain possible.
Two functionally distinct oligodendrocyte-lineage populations exist in the adult CNS: OPCs (oligodendrocyte precursor cells, NG2⁺/PDGFRα⁺/OLIG2⁺) — cycling or quiescent progenitors (~5% of adult CNS cells); and mature oligodendrocytes (MO, CC1⁺/MBP⁺/PLP1⁺/MOG⁺) — terminally differentiated, post-mitotic myelin-forming cells.
Structure — OPC vs. Mature Oligodendrocyte
OPC (Oligodendrocyte Precursor Cell)
Bipolar/stellate soma (8–15 µm); NG2 (CSPG4) pericellular matrix; PDGFRα responds to PDGF-AA (main proliferative signal). Express functional AMPA and NMDA receptors — activity-dependent myelination (active axons → glutamate → OPC Ca²⁺ → mTOR → MBP translation). Cycle slowly or quiescently; respond to demyelinating injury by rapid proliferation. Inhibitory signals: LINGO-1, Nogo-A, CSPGs, PSA-NCAM.
Mature Oligodendrocyte
Larger soma (15–20 µm); processes extend to axons (up to 200–300 µm away), spiral ~150 times around the internode, and compact into myelin. Post-mitotic, long-lived (years). Required TFs: YY1, ZEB2, MYRF (master OL differentiation TF — cleaves from ER membrane → nucleus → drives MBP, PLP, MOG transcription). Thyroid hormone (T3) is a potent pro-myelination signal; deficiency in neonates → hypomyelination → intellectual disability.
| Myelin protein | Abundance | Location / Function |
|---|---|---|
| PLP1/DM20 | ~50% myelin protein | 4-pass transmembrane; most abundant CNS myelin protein; stabilises extracellular intraperiod line; PLP1 mutation → PMD/SPG2 |
| MBP | ~30% myelin protein | Positively charged; bridges adjacent cytoplasmic leaflets via electrostatic interactions → compacts the major dense line; target of MS autoimmune response |
| MOG | ~0.01–0.05% | Outermost lamella only; target of anti-MOG IgG in MOGAD; expressed exclusively on external myelin surface; activates complement |
| MAG | Minor | Inner periaxonal space; mediates axon-OL contact via axonal NgR1; inhibits axon regeneration after demyelination |
| CNP | Minor | Non-compact regions (paranodes, inner tongue); 2′,3′-cyclic nucleotide 3′-phosphodiesterase; may maintain non-compact myelin structure |
Function — Myelination Process and Saltatory Conduction
Remyelinated internodes are shorter and thinner than original — partially restoring conduction but with lower safety factor than original myelin.
| Axon type | Diameter | Conduction velocity | Myelinated? |
|---|---|---|---|
| Aα (motor, proprioception) | 13–20 µm | 70–120 m/s | Yes (thick) |
| Aβ (tactile) | 6–12 µm | 33–75 m/s | Yes |
| Aδ (pain, temperature) | 1–5 µm | 3–30 m/s | Lightly |
| C fibres (pain, autonomic) | 0.2–1.5 µm | 0.5–2 m/s | No |
Function — MCT1 Metabolic Support of Axons
Beyond insulation, oligodendrocytes provide critical metabolic support to ensheathed axons via the monocarboxylate transporter 1 (MCT1) expressed in compact myelin — an OL function independent of myelin insulation itself:
This is analogous to the astrocyte-neuron lactate shuttle (ANLS), but delivered directly through the myelin sheath to ensheathed axons. MCT1 is encoded by SLC16A1.
Lifecycle — OPC Differentiation and Remyelination Failure in MS
OPC specification and migration. OPCs originate from ventral ventricular zone progenitors co-expressing OLIG2 + NKX2.2 in three waves (mouse: E12.5 from MGE, E15.5 from LGE/CGE, postnatally from cortex). OPCs proliferate in response to PDGF-AA, FGF2, and EGF; migrate along axon tracts guided by semaphorin and netrin gradients; populate both white and grey matter. Adult OPCs are the only mitotically active CNS cells under homeostatic conditions.
Adult remyelination. After demyelinating injury, resident OPCs proliferate (within days), migrate to the lesion (weeks), and differentiate into new myelinating OLs (weeks–months). In MS chronic lesions, OPCs are often present but fail to differentiate — "remyelination failure" — due to:
Pathology
Multiple Sclerosis (MS)
CNS-infiltrating CD4⁺ Th1/Th17 cells (recognising myelin peptides in HLA-DRB1*15:01 context), CD8⁺ T cells, B cells, and macrophages destroy oligodendrocytes and myelin via TRAIL, perforin/granzyme, Fas-FasL, and complement. Axons degenerate in chronic disease (Wallerian degeneration) — substrate of irreversible disability. DMTs target the adaptive immune infiltrate: natalizumab (anti-α4-integrin), ocrelizumab (anti-CD20), siponimod (S1PR1/5).
MOGAD (MOG Antibody Disease)
Anti-MOG IgG1 targets the outermost myelin lamella → complement activation + ADCC → OL and myelin destruction. Presents as ADEM, bilateral optic neuritis, or transverse myelitis. Distinguished from MS by bilateral optic involvement, absence of OCBs, good response to steroids and rituximab.
PML (Progressive Multifocal Leukoencephalopathy)
JC virus specifically infects OPCs and mature OLs (using 5-HT₂A as entry receptor) → OL lysis → widespread demyelination. Occurs in immunosuppressed individuals (natalizumab: ~1:1000; rituximab; HIV/AIDS). No antiviral therapy; treatment is immune reconstitution (IRIS may paradoxically worsen initial outcome).
Pelizaeus-Merzbacher Disease (PMD)
X-linked recessive PLP1 mutations (duplications, point mutations, deletions) → hypomyelination/dysmyelination → nystagmus (infancy), hypotonia, ataxia, dysarthria, progressive spastic quadriplegia. A242V point mutation → ER retention of PLP1 → oligodendrocyte ER stress (UPR) → apoptosis. Fatal in early adulthood (severe PMD); milder SPG2 allelic variant.
Vanishing White Matter Disease
AR mutations in EIF2B1–5 (eIF2B subunits — GEF recycling eIF2-GDP to eIF2-GTP) → constitutive ISR activation → astrocyte dysfunction → secondary OL failure and white matter vanishing on MRI. Precipitated by febrile illness, head trauma, or fright (→ eIF2α-P → worsens already-impaired eIF2B function).
Adrenoleukodystrophy (X-ALD)
X-linked mutations in ABCD1 (peroxisomal VLCFA transporter) → very long chain fatty acid accumulation in CNS myelin → demyelination (cerebral ALD in boys) or slowly progressive myelopathy (AMN in adults). Lorenzo’s oil may slow progression; haematopoietic stem cell transplantation is treatment of choice for early cerebral ALD.
Cross-Atlas Connections
References
- Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 7th ed. W.W. Norton; 2022. NCBI Bookshelf
- Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier; 2021. Elsevier
- Funfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485(7399):517–521. doi:10.1038/nature11007 · PubMed 22622581
- Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244–252. doi:10.1038/nature09614 · PubMed 21068833